Search Results
Results found for "Peter Robert Banks"
- Inside the New Dr. GPCR Ecosystem: Learning, Insight, and Momentum for 2026
After a brief pause over the holidays and last month, weâre back in full forceâdesigned to help you make
- From Pipettes to Platforms: The Evolution of GPCR Research
The Era of Cold Fingers and Patience Back then, GPCR signaling experiments werenât elegant; they were
- How GPCR Spatial Signaling Sparked a Scientific Journey
Many GPCR scientists trace their origin story back to a single unexpected spark. Not a grand plan.
- The Hidden Operating Cadence Thatâs Actually Driving Your Biotech
The CEO oscillates between fire-fighting and âletâs step back and think,â depending on emotional energy
- Scientific Isolation: The Real Reason Early Biotechs Lose Traction
structure, traction, visibility: these are the forces that pull a biotech out of scientific isolation and back
- How Schild Analysis Protects Your Conclusions in GPCR Research
Welcome back GPCR Fans, Clean data can still mislead if the underlying assumptions arenât tested.
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
UNC and Terry's Corner We'll continue to update this section as new videos are released â so check back
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
Every time a problem arises, we trace it back to its root cause, implementing changes that prevent its
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, youâre already This is where funders, peers, and biotech scouts are watching. Access peer insights on allosteric modulators and biased ligands.
- Curve Shifts Donât Lie, But Your Eyes Might
And once you make that shift, youâll never go back.
- Understanding the Journey: Catherine Demery's Path to Addiction Science
It was mostly just because, I need to be back in the lab.â
- Amylin Receptor Signaling: Three Receptors From One, and How to Profile Each
Covering the full arc of discovery, from screening to mechanistic profiling, they enable confident rank-ordering β-arrestin readouts, the subtypes that matter for weight loss, and ortholog assays that tie bench data back
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
With over 21,000 views  and 7,785 downloads  from Volume I, the Signal Transduction  Research Topic is back
- đ° GPCR Weekly News, June 5 to 11, 2023
Our website is updated as we confirm speakers so please check back often.
- đ° GPCR Weekly News, February 13 to 19, 2023
From outside to inside and back again: the lysophosphatidic acid-CCN axis in signal transduction.
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Welcome back GPCR fans, The pace of GPCR innovation is accelerating at a rate that can be difficult to
- đ° GPCR Weekly News, August 28 to September 3, 2023
pathophysiology and treatment of CNS disorders GPCRs in Oncology and Immunology From outside to inside and back
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
a cold email from a biologist heâd never met, asking if he could synthesize a molecule âwhen youâre back
- đ° Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei Heptares to take back
- đ° GPCR Weekly News, November 20 to 26, 2023
with Multispan Cell Engineering and Assay Services $3bn sales potential for drug Sosei Heptares wants back
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Welcome back GPCR lovers, In pharmacology, the wrong interpretation of antagonist behavior can derail Avoid the professional threat of falling behind your peers by accessing the same insights that are driving
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
Unexpected outcomes typically trace back to a single issue: transferring assumptions from idealized models Kenakin demonstrates how premature stopping mis-ranks compounds, particularly when tracer and displacer
- âľSailing the GPCR Seas: Your Weekly Research Voyage! ⌿ Nov 11 - 17, 2024
with AEF0217 in young adults with Down syndrome Novartis pays SchrĂśdinger $150M, bets billions on the back
- đ° GPCR Weekly News, December 18 to 31, 2023
Warm greetings and a resounding welcome back to our GPCR Weekly Newsletter, rejuvenated after the festive
- Chemokine receptor-targeted drug discovery: progress and challenges
binds to CCR1, CCR3 and CCR5, and induces different patterns of receptor recycling where CCR5 recycles back
- The Real Cost of Strategic Overload in Biotech
. đ Biotech fundraising rewards conviction backed by disciplined sequencing.
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⌿ Nov 24 - Dec 1, 2024
We're zooming back to the future of GPCR discoveries.
- How Early Strategic Decision Making Creates Alignment and Better Results
đ Most founders look back at the end of the year and try to make sense of the results.
- đ° GPCR Weekly News
We're excited to be back and share our weekly newsletter!
- Adhesion GPCR Consortium Newsletter - May 2024
The excitement I felt when I first attended back in Boston is the same one I feel now that I am the organizer






















